BSTE Biosite (MM)

Biosite(R) Incorporated Adds Two Vice Presidents to Executive Management Leading Bio-Medical Company Adds Prominent Emergency Medicine Physician and Seasoned Quality Assurance Executive to Team SAN DIEGO, June 27 /PRNewswire-FirstCall/ -- Biosite(R) Incorporated (NASDAQ:BSTE) today announced Norman Paradis, M.D., has been named vice president medical affairs and S. Elaine Walton has been promoted to vice president, quality assurance and program management. Dr. Paradis will provide medical guidance for clinical trial design, regulatory submissions, new product prioritization, medical education, and product strategy and positioning. Walton, who has more than 20 years of healthcare industry experience, is responsible for quality assurance, compliance, quality system training, operational audits and program management. "With the expansion of our business, it is important for us to broaden expertise within our management team," said Kim Blickenstaff, Biosite chairman and chief executive officer. "Both Norm and Elaine possess experience and skills that will contribute to Biosite's continued success and market leadership." Dr. Paradis has 20 years of clinical, research and administrative experience in emergency medicine. Most recently, he was professor of surgery and medicine at the University of Colorado, and senior medical director of emergency medicine at University of Colorado Hospital, where he headed a research group with active programs in real-time diagnostic technology, hemodynamics, hypothermia, stroke biomarkers, fibrinolytics and emergency cardiopulmonary bypass. Active in organized medicine, Dr. Paradis has been a member of numerous medical professional organizations, including the Society for Academic Emergency Medicine (SAEM), Society of Critical Care Medicine (SCCM), the American College of Emergency Medicine (ACEP), and the American Academy of Emergency Medicine (AAEM) among others. Dr. Paradis was one of the founding members of SAEM's Reperfusion Working Group, and has been active in the American Heart Association (AHA), serving on the Advanced Cardiac Life Support (ACLS) Subcommittee for more than 10 years. He is a fellow of the American Board of Emergency Medicine. Dr. Paradis is on the editorial boards of The American Journal of Emergency Medicine, Resuscitation, and the Critical Illness section of the Journal of the American Medical Association (JAMA). He has published more than 60 scientific articles and texts. Walton joined Biosite in 1997 as the director of program management and was promoted to senior director in 2004. She created the Company's project management office, successfully leading multi-disciplinary teams through processes leading to new product commercialization and ongoing product improvement. Walton's expertise contributed to the expansion of Biosite's product offerings, which consisted of a single drug screening product, the Triage Drugs of Abuse Panel, in 1997 and today include more than 10 products addressing a variety of acute diseases and conditions. Prior to joining Biosite, Walton held the positions of vice president of quality assurance/compliance/project management and vice president operations for Nichols Institute Diagnostics (a division of Corning Nichols & Quest Diagnostics), a biotechnology company that develops, manufactures and markets medical diagnostic tests and instrumentation. Prior to that, she obtained clinical and medical technology experience at SmithKline Clinical Laboratory. Walton is a Certified Regulatory Affairs Professional, a Certified Quality Manager and a Certified Project Management Professional. She holds a bachelor's degree in biology with an emphasis on medical technology from California State University of Hayward. About Biosite Incorporated Biosite Incorporated is a leading bio-medical company commercializing proteomics discoveries for the advancement of medical diagnosis. The Company's products contribute to improvements in medical care by aiding physicians in the diagnosis of critical diseases and health conditions. Biosite's Triage(R) rapid diagnostics are used in approximately 50 percent of U.S. hospitals and in over 50 international markets. Information on Biosite can be found at http://www.biosite.com/. Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered trademarks of Biosite Incorporated. DATASOURCE: Biosite Incorporated CONTACT: Nadine Padilla, VP, Corporate & Investor Relations of Biosite Incorporated, +1-858-455-4808, ext. 3187, Web site: http://www.biosite.com/ Company News On-Call: http://www.prnewswire.com/comp/116737.html

Copyright